


Medicare Increases Hospital Outpatient and ASC Payment for LimFlow TADV

Effective January 1, 2025, Medicare will reassign the LimFlow TADV procedure (CPT 0620T) from New Technology APC 1578 to New Technology APC 1579, which has an average payment amount of \$35,001 in the hospital outpatient department (HOPD) and an average payment of \$31,714 in the ambulatory surgical center (ASC).

This positive reassignment represents a 27% increase in hospital outpatient patient and a 29% increase in ASC payment for LimFlow TADV from 2024. Additionally, the facility payment for LimFlow TADV is not subject to multiple procedure discounting. Medicare finalized these positive updates in the 2025 Medicare Hospital Outpatient Prospective Payment System Rule released on Friday, November 5, 2024.

YoY Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) National Average Medicare Payment



As a reminder, effective October 1, 2024, hospital inpatient LimFlow TADV cases are eligible for an incremental payment of up to \$16,250 from Medicare in addition to the applicable MS-DRG payment for the case. This incremental reimbursement is called a “New Technology Add-on Payment” or NTAP. More information is available at: <https://limflow.com/us/reimbursement-resources>.

Sources:
 Medicare FFS Outpatient Hospital Rates effective January 1, 2024 through December 31, 2024.; Source: CY 2024 OPSS Final Rule; hospital impact file, Addendum A
 Medicare FFS Outpatient Hospital Rates effective January 1, 2025 through December 31, 2025.; Source: CY 2025 OPSS Final Rule; hospital impact file, Addendum A
 LimFlow NTAP finalized in FY 2025 IPPS Final Rule (CMS-1808-F).

Disclaimer: The coding, coverage, and payment information contained herein is gathered from various resources and is subject to change without notice. Inari-LimFlow cannot guarantee success in obtaining third-party insurance payments. Third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine and submit appropriate codes, charges, and modifiers for services that are rendered. Providers should contact their third-party payers for specific information on their coding, coverage, and payment policies.

Important Safety Information: LimFlow System and LimFlow Stent Grafts Intended Use/Indications for Use: The LimFlow System and LimFlow Stent Grafts are indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. Contraindications: Patients with deep venous thrombus in target vein; Patients with uncorrected bleeding disorders or patients who cannot receive anticoagulation or antiplatelet aggregation therapy. Warnings and Precautions: Use in patients with concomitant hepatic insufficiency has not been evaluated; Use in patients with poor cardiac output, e.g., NYHA Class IV, has not been evaluated; Use in pregnant and breastfeeding women has not been evaluated; Implanting the device in the distal half of the calcaneus may result in stent fracture. Adverse Events: Acute renal impairment requiring dialysis; Cardiac arrest; Death; Embolization; Graft rupture, trans-graft leak, site leak; Hematoma; Insufficient blood flow to foot; Ischemia; Myocardial infarction; Occlusion; Pain; Peripheral edema; Procedural bleeding; Restenosis of stented segment; Sepsis / Infection; Stent damage, implant migration; Stent graft fracture; Stent graft misplacement, deformation, or migration; The need for surgical or endovascular interventions to rectify an access site problem; Thrombosis; Vessel dissection, perforation, injury; Vessel spasm. Please reference product instructions for use for more information regarding indications, warnings, precautions, contraindications, and adverse events. LimFlow ARC Intended Use/Indications for Use: The LimFlow ARC is intended to facilitate placement and positioning of guidewires and catheters within the peripheral vasculature. The LimFlow ARC is not intended for use in the coronary or cerebral vasculature. LimFlow V-Ceiver Intended Use/Indications for Use: The LimFlow V-Ceiver is intended for use in the cardiovascular system to manipulate and retrieve guidewires specified in the IFU. LimFlow Vector Intended Use/Indications for Use: The LimFlow Vector is intended for the treatment of vascular disorders and more particularly for excising or disrupting venous valves.

Caution: Federal (USA) law restricts these devices to sale by or on the order of a licensed healthcare practitioner.

All trademarks and copyrights are property of their respective owners. LimFlow is a proud member of the Inari Medical Family.